GlaxoSmithKline PLC Result of General Meeting (1952A)
December 18 2014 - 6:48AM
UK Regulatory
TIDMGSK
RNS Number : 1952A
GlaxoSmithKline PLC
18 December 2014
Issued: Thursday 18 December 2014, London UK - LSE
Announcement
Result of General Meeting relating to the proposed major
transaction with Novartis
GlaxoSmithKline plc (GSK) announces that at its General Meeting
held earlier today, the sole resolution was passed by shareholders
by an overwhelming majority. As previously announced, the
transaction is expected to complete during the first half of 2015,
subject to approvals.
GlaxoSmithKline General Meeting Poll Results
The following table shows the votes cast in respect of the
resolution:
Resolution Total votes % Total votes % Total votes Votes
for(*) against cast withheld(**)
Proposed major
transaction
with Novartis
AG 3,606,194,474 99.79 7,672,471 0.21 3,613,866,945 11,617,644
-------------- ------ ------------ ----- -------------- --------------
In accordance with Listing Rule 9.6.2, a copy of the resolution
will be submitted to the UK Listing Authority and will in due
course be available for inspection at
www.morningstar.co.uk/uk/NSM.
Notes:
* Includes discretionary votes.
** A vote withheld is not a vote in law and is not counted in
the calculation of the proportion of votes "For" or "Against" a
resolution.
The following table provides further relevant information:
Issued share capital
(excluding Treasury Shares) 4,863,747,114
Total votes cast and votes
withheld lodged as a % of
GSK's issued share capital
(excluding Treasury Shares) 74.54
--------------
Total shareholder population 139,567
--------------
Total number of proxies lodged 12,457
--------------
% of shareholders who lodged
proxies 8.93
--------------
Number of shareholders, corporate
representatives and proxies
who attended the General Meeting 75
--------------
V A Whyte
Company Secretary
GSK - one of the world's leading research-based pharmaceutical
and healthcare companies - is committed to improving the quality of
human life by enabling people to do more, feel better and live
longer. For further information please visit www.gsk.com.
GSK enquiries:
UK Media enquiries: David Mawdsley +44 (0) 20 8047 (London)
5502
Simon Steel +44 (0) 20 8047 (London)
5502
Sarah Spencer + 44 (0) 20 8047 (London)
5502
US Media enquiries: Stephen Rea +1 215 751 4394 (Philadelphia)
Sarah Alspach +1 202 715 1048 (Washington)
Mary Anne Rhyne +1 919 483 0492 (North Carolina)
Analyst/Investor Ziba Shamsi +44 (0) 20 8047 (London)
enquiries: 3289
Tom Curry + 1 215 751 5419 (Philadelphia)
Gary Davies +44 (0) 20 8047 (London)
5503
James Dodwell +44 (0) 20 8047 (London)
2406
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Information regarding forward-looking statements
This announcement includes statements that are, or may be deemed
to be, "forward-looking statements". These forward-looking statements
can be identified by the use of forward-looking terminology,
including the terms "believes", "estimates", "plans", "projects",
"anticipates", "expects", "intends", "may", "will", or "should"
or, in each case, their negative or other variations or comparable
terminology, or by discussions of strategy, plans, objectives,
goals, future events or intentions. These forward-looking statements
include all matters that are not historical facts. They appear
in a number of places throughout this announcement and include,
but are not limited to, statements regarding GSK's intentions,
beliefs or current expectations concerning, among other things,
GSK's business, results of operations, financial position, prospects,
growth, strategies and the industry in which it operates as
well as those of the Novartis businesses that are the subject
of the transaction. By their nature, forward-looking statements
involve risk and uncertainty because they relate to future events
and circumstances. Forward-looking statements are not guarantees
of future performance and the actual results of GSK's operations
and financial position, and the development of the markets and
the industry in which GSK operates, may differ materially from
those described in, or suggested by, the forward-looking statements
contained in this announcement. The same applies in respect
of the Novartis Businesses that are the subject of the transaction.
In addition, even if the results of operations, financial position
and the development of the markets and the industry in which
GSK operates are consistent with the forward-looking statements
contained in this announcement, those results or developments
may not be indicative of results or developments in subsequent
periods. A number of factors could cause results and developments
to differ materially from those expressed or implied by the
forward-looking statements including, without limitation, general
economic and business conditions, industry trends, competition,
changes in regulation, currency fluctuations, changes in its
business strategy, political and economic uncertainty and other
factors discussed in this announcement.
Forward-looking statements may, and often do, differ materially
from actual results. Any forward-looking statements in this
announcement speak only as of their respective dates, reflect
GSK's current view with respect to future events and are subject
to risks relating to future events and other risks, uncertainties
and assumptions relating to GSK's operations, results of operations
and growth strategy. You should specifically consider the factors
identified in this document, in addition to the risk factors
that may affect GSK's operations which are described under "Risk
Factors" in the Company's 2013 Annual Report on Form 20-F, which
could cause actual results to differ before making any decision
in relation to the Transaction as well as those of the Novartis
businesses that are the subject of the transaction. Subject
to the requirements of the FCA, the London Stock Exchange, the
Listing Rules and the Disclosure and Transparency Rules (and/or
any regulatory requirements) or applicable law, GSK explicitly
disclaims any obligation or undertaking publicly to release
the result of any revisions to any forward-looking statements
in this announcement that may occur due to any change in GSK's
expectations or to reflect events or circumstances after the
date of this announcement.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
This information is provided by RNS
The company news service from the London Stock Exchange
END
REGLLFSFFRLTLIS
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
Gsk (LSE:GSK)
Historical Stock Chart
From May 2023 to May 2024